PDCD1 and cancer: A meta-analysis evaluating sex differences in response to anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapies in combination with immunotherapies in cancer patients showed no significant difference in overall survival (OS) or progression-free survival (PFS) between the sexes.